BioWorld: The Daily Biopharmaceutical and Medical Technology …
These cookies are used to enable social media sharing or “like” buttons on our services. They also provide the ability to link your account or engage with our content on or through a social media platform such as Facebook, Twitter or LinkedIn.
Arrowhead seeks clearance to begin clinical trials with ARO-ALK7 …
Dec 4, 2024 · Arrowhead Pharmaceuticals Inc. has filed a request to the New Zealand Medicines and Medical Devices Safety Authority for regulatory clearance to initiate a first-in-human trial of ARO-ALK7, an RNA interference (RNAi) therapeutic being developed to treat obesity.
Biopharma financings surge to $86.2B in 2024, with $8.7B in …
Oct 4, 2024 · Biopharma financings continued to outperform over the first nine months of 2024, hitting $86.2 billion, a 75% increase from the $49.35 billion raised during the same period in 2023. September alone saw a significant boost from the prior month, with financings more than doubling to $8.7 billion from $3.5 billion in August.
Alloplex’s Suplexa reawakens immune cells to fight cancer
Nov 26, 2024 · When it comes to cell therapy, Alloplex Biotherapeutics Inc. CEO Frank Borriello said he believes that autologous, personalized therapy is the only thing that makes sense. “The allure of an off-the-shelf therapy has been such a magnet. It sucked in a lot of companies into that dream, and I'm sorry to say, it hasn't really worked out for them,” he told BioWorld. Instead, Borriello said he ...
Pfizer patents new compounds targeting GTPase KRAS
Oct 30, 2024 · Pfizer Inc. has disclosed drugs targeting GTPase KRAS and its mutant forms reported to be useful for the treatment of cancer.
BioWorld: The Daily Biopharmaceutical News Source
Daily news and analysis of the global biotechnology and pharmaceutical industries. In-depth coverage of business, financing, regulation, science, innovation, drug approvals, clinical trials and more.
US lawmakers launch year-end push for PBM reforms
Dec 10, 2024 · If a bipartisan group of U.S. House members has its way, at least some of the legislation congressional committees have passed to target pharmacy benefit manager (PBM) practices could yet make it into law this year. That is if congressional leaders listen to the rank-and-file members.
Mechanism underlying so-called idiopathic autism inception …
Dec 13, 2024 · Investigators at the Institute for Research in Biomedicine (IRB Barcelona) have unraveled how and why the absence of a neuronal microexon in cytoplasmic polyadenylation element-binding 4 (CPEB4) gives rise to autism. In 2018, investigators from IRB, co-led by Raúl Méndez, identified the overt correlation between defects in CPEB4 and the onset of autism. However, the previous work did not ...
| BioWorld
Oct 17, 2024 · As a new BioWorld new investigative report shows, decades of research excluding women from clinical trials and investment decisions made in male-dominated boardrooms have led to half the world’s health needs being underserved.Of the drug development companies working on women's health solutions, the proportion of …
Kaken Pharmaceutical divulges new STAT6 inhibitors - BioWorld
Apr 23, 2024 · Kaken Pharmaceutical Co. Ltd. has synthesized signal transducer and activator of transcription 6 (STAT6) inhibitors reported to be useful for the treatment of asthma, allergic rhinitis, chronic obstructive pulmonary disease, atopic dermatitis, nasal polyps, bullous pemphigoid, prurigo and urticaria, among others.